Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K August 08, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 08 August 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (the 'Company')

Transaction notification

Details of PDMR/person closely associated with

1. them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, Human Resources

Initial notification/

c) amendment Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

momo

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of

3. transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description Ordinary shares of 25 pence of each ('Ordinary Shares')
a) the ISIN: GB0009252882

financial instrument

Nature of

b) the Sale of Ordinary Shares

transaction

Price(s) Price(s) Volume(s)
c) and volume(s)

£15.9462 40,000

Aggregated n/a (single transaction)

information

d) Aggregated volume Price

e) Date of 2018-08-07

the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

transaction

Place

f) of London Stock Exchange

the transaction (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: August 8, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc